Unibest
← Back to patent-cliff list

Perfluorohexyloctane

Tier C — Watch / trade

Perfluorohexyloctane

Novaliq Gmbh
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Lipid

Brand:NovaTears, Heng Qin, Miebo

Indications (approved):Dry eye disease, Dry eye syndrome

Regional status

US
Approved
2023-05-18
EU
-
China
Approved
2025-06-30
Japan
-

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Sign in to view factories →

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Perfluorohexyloctane?

Approved indications include: Dry eye disease, Dry eye syndrome.

When does the Perfluorohexyloctane patent expire?

No public expiry year is available for Perfluorohexyloctane yet; this page updates once verified.

How do I get a quote for Perfluorohexyloctane intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27